IFP Advisors’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.55K Sell
114
-16
-12% -$1.03K ﹤0.01% 3495
2026
Q1
$7.33K Sell
130
-18
-12% -$1.17K ﹤0.01% 3322
2025
Q4
$11.9K Buy
148
+68
+85% +$4.57K ﹤0.01% 2969
2025
Q3
$3.9K Buy
+80
New +$4.95K ﹤0.01% 3383
2025
Q2
Sell
-10
Closed -$662 3457
2025
Q1
$636 Sell
10
-3
-23% -$204 ﹤0.01% 3412
2024
Q4
$1.01K Buy
13
+3
+30% +$241 ﹤0.01% 3275
2024
Q3
$804 Hold
10
﹤0.01% 3101
2024
Q2
$827 Hold
10
﹤0.01% 3021
2024
Q1
$854 Hold
10
﹤0.01% 2884
2023
Q4
$855 Hold
10
﹤0.01% 2828
2023
Q3
$896 Sell
10
-203
-95% -$18.1K ﹤0.01% 3022
2023
Q2
$18.1K Sell
213
-84
-28% -$7.1K ﹤0.01% 2053
2023
Q1
$27K Buy
297
+47
+19% +$3.81K ﹤0.01% 1887
2022
Q4
$26K Buy
250
+16
+7% +$1.29K ﹤0.01% 2689
2022
Q3
$24K Buy
234
+8
+4% +$574 ﹤0.01% 2917
2022
Q2
$21K Hold
226
﹤0.01% 2793
2022
Q1
$21K Buy
+226
New +$12.3K ﹤0.01% 2793
2021
Q1
Sell
-530
Closed -$65.6K 3089
2020
Q4
$62K Buy
530
+446
+531% +$48K ﹤0.01% 1348
2020
Q3
$7K Buy
84
+52
+163% +$4.54K ﹤0.01% 2037
2020
Q2
$3K Buy
32
+10
+45% +$1.01K ﹤0.01% 2265
2020
Q1
$3K Buy
+22
New +$2.39K ﹤0.01% 2246
2019
Q4
Sell
-26
Closed -$3.15K 2952
2019
Q3
$3K Buy
+26
New +$3.3K ﹤0.01% 2539
2019
Q1
$3K Buy
41
+29
+242% +$2.64K ﹤0.01% 2006
2018
Q4
$1K Sell
12
-101
-89% -$10.6K ﹤0.01% 3310
2018
Q3
$13K Sell
113
-123
-52% -$12.7K ﹤0.01% 2696
2018
Q2
$21K Sell
236
-151
-39% -$12.8K ﹤0.01% 2431
2018
Q1
$22K Hold
387
﹤0.01% 2321
2017
Q4
$22K Hold
387
﹤0.01% 2354
2017
Q3
$17K Hold
387
﹤0.01% 2705
2017
Q2
$15K Buy
387
+266
+220% +$10.9K ﹤0.01% 2752
2017
Q1
$5K Hold
121
﹤0.01% 3287
2016
Q4
$5K Sell
121
-14
-10% -$528 ﹤0.01% 3291
2016
Q3
$5K Buy
135
+108
+400% +$3.71K ﹤0.01% 3227
2016
Q2
$1K Sell
27
-14
-34% -$423 ﹤0.01% 3624
2016
Q1
$3K Buy
41
+14
+52% +$452 ﹤0.01% 2003
2015
Q4
$1K Buy
+27
New +$876 ﹤0.01% 3520

Other funds holding HAE

IFP Advisors's HAE Position: Q2 2026 in Review

IFP Advisors reduced its Haemonetics (HAE) stake by 12% in Q2 2026, selling an estimated $1.03K and leaving 114 shares worth $8.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3495.

IFP Advisors first reported a position in HAE in Q4 2015 and has held it in 36 quarters since. The position peaked at $62K in Q4 2020. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • IFP Advisors held 114 shares of Haemonetics worth $8.55K as of Q2 2026.
  • IFP Advisors sold 16 Haemonetics shares in Q2 2026, an estimated $1.03K.
  • Haemonetics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3495 holding.
  • IFP Advisors first reported a position in Haemonetics in Q4 2015 and has held it in 36 quarters since.
  • IFP Advisors's Haemonetics position peaked at $62K in Q4 2020.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.